KHB(SZ:002022)2023-05-19 08:17Company Overview - Shanghai Kehua Bio-engineering Co., Ltd. was established in 1981 and is the first company listed on the Shenzhen Stock Exchange's SME board in the IVD sector [2] - The company specializes in the R&D, production, and sales of in vitro diagnostic reagents and medical testing instruments, covering molecular diagnostics, biochemical diagnostics, immunodiagnostics, and point-of-care testing [2] - Kehua's products are distributed across over 30 provinces and municipalities in China, serving more than 12,000 hospitals and over 500 disease control centers, blood centers, blood stations, biopharmaceutical companies, and research institutes, with exports to multiple countries [2] Competitive Advantages - Leading R&D and technical advantages in the IVD field, with a focus on continuous investment in research and development [3] - Strong industry foundation and comprehensive competitive advantages through integrated biotechnological, medical device manufacturing, and collaborative innovation platforms [3] - Strict production and quality control processes, certified by GMP and ISO13485, ensuring high-quality products [3] - A nationwide marketing team with a professional background in biology and medicine, providing a stable customer base and channel resources [3] - International market expansion with products exported to multiple countries, leveraging the sales network of its Italian subsidiary [3] Future Development Directions - Focus on internal capabilities by increasing R&D investment and improving business integration within the IVD industry [3] - Collaborate with international giants as opportunities for cooperation with foreign and domestic companies increase [3] - Actively expand overseas business based on past international experience [3] Industry Trends and Company Positioning - Embracing centralized procurement to optimize the supply chain and enhance cost efficiency in response to rapid market development and national policy advocacy [4] - The acquisition of a major stake by Gree Real Estate signifies a strategic move into the biopharmaceutical and healthcare sectors, supporting long-term stable development [4] - The company has decided not to adjust the conversion price of its convertible bonds, reflecting confidence in its long-term stable growth and intrinsic value [4]